Janssen Reminyl ad violations
Executive Summary
Janssen Reminyl ads suggesting "Reminyl is safe and effective for the treatment of Alzheimer's patient subgroups with probable vascular dementia are misleading because they suggest a specific benefit linked to the vascular dementia when none has been demonstrated," FDA says in Nov. 20 letter. FDA also objects to company's statement that Reminyl is a "unique agent with consistent results"...